The role of phosphoglycerate mutase 1 in tumor aerobic glycolysis and its potential therapeutic implications

International Journal of Cancer

Volumn 135, Issue 9, 2014, Pages 1991-1996

  Jiang, Xiangli ^a,b   Sun, Qian ^a,b   Li, Hui ^a,b   Li, Kai ^a   Ren, Xiubao ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

aerobic glycolysis; cancer therapy; PGAM1; Warburg effect

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; FRUCTOSE 6 PHOSPHATE; GLUCOSE 6 PHOSPHATE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MUTASE; PHOPHOGLYCERATE MUTASE 1; PHOPHOGLYCERATE MUTASE 1 INHIBITOR; PHOPHOGLYCERATE MUTASE 2; PYRUVATE KINASE; PYRUVATE KINASE M2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RIBOSE 5 PHOSPHATE; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; CANCER CELL; CANCER CELL METABOLISM; CANCER INHIBITION; CELL METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; GENE; GLYCOLYSIS; HUMAN; METABOLIC REGULATION; MOLECULARLY TARGETED THERAPY; PENTOSE PHOSPHATE CYCLE; PGAM1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

AEROBIC GLYCOLYSIS; CANCER THERAPY; PGAM1; WARBURG EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; GLYCOLYSIS; HUMANS; NEOPLASMS; OXYGEN; PHOSPHOGLYCERATE MUTASE;

EID: 84906223319     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28637     Document Type: Review

References (63)

1. Warburg O, Wind F, Negelein E,. The metabolism of tumors in the body. J Gen Physiol 1927; 8: 519-30.
2. Racker E,. Bioenergetics and the problem of tumor growth. Am Sci 1972; 60: 56-63.
3. Ward PS, Thompson CB,. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012; 21: 297-308.
4. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
5. Wolf A, Agnihotri S, Micallef J, et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 2011; 208: 313-26.
6. Mathupala SP, Rempel A, Pedersen PL,. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 2001; 276: 43407-12.
7. Possemato R, Marks KM, Shaul YD, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011; 476: 346-50.
8. Locasale JW, Grassian AR, Melman T, et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 2011; 43: 869-74.
9. Shim H, Dolde C, Lewis BC, et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA 1997; 94: 6658-63.
10. Le A, Cooper CR, Gouw AM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 2010; 107: 2037-42.
11. Szablewski L,. Expression of glucose transporters in cancers. Biochim Biophys Acta 2013; 1835: 164-9.
12. Fothergill-Gilmore LA, Watson HC,. The phosphoglycerate mutases. Adv Enzymol Relat Areas Mol Biol 1989; 62: 227-313.
13. Buhrens RI, Amelung JT, Reymond MA, et al. Protein expression in human non-small cell lung cancer: a systematic database. Pathobiology 2009; 76: 277-85.
14. Shen J, Wang W, Wu J, et al. Comparative proteomic profiling of human bile reveals SSP411 as a novel biomarker of cholangiocarcinoma. PLoS One 2012; 7: e47476.
15. Li C, Xiao Z, Chen Z, et al. Proteome analysis of human lung squamous carcinoma. Proteomics 2006; 6: 547-58.
16. Durany N, Joseph J, Campo E, et al. Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and enolase activity and isoenzymes in lung, colon and liver carcinomas. Br J Cancer 1997; 75: 969-77.
17. Evans MJ, Saghatelian A, Sorensen EJ, et al. Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling. Nat Biotechnol 2005; 23: 1303-7.
18. Ren F, Wu H, Lei Y, et al. Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma. Mol Cancer 2010; 9: 81.
19. Shalom-Barak T, Knaus UG,. A p21-activated kinase-controlled metabolic switch up-regulates phagocyte NADPH oxidase. J Biol Chem 2002; 277: 40659-65.
20. Evans MJ, Morris GM, Wu J, et al. Mechanistic and structural requirements for active site labeling of phosphoglycerate mutase by spiroepoxides. Mol Biosyst 2007; 3: 495-506.
21. Kashiwaya Y, Sato K, Tsuchiya N, et al. Control of glucose utilization in working perfused rat heart. J Biol Chem 1994; 269: 25502-14.
22. Rodwell VW, Towne JC, Grisolia S,. The kinetic properties of yeast and muscle phosphoglyceric acid mutase. J Biol Chem 1957; 228: 875-90.
23. Hass LF, Place AR, Miller KB, et al. The isolation and characterization of an active site phosphohistidine peptide from human erythrocyte bisphosphoglycerate synthase. Biochem Biophys Res Commun 1980; 95: 1570-6.
24. Yanagawa S, Hitomi K, Sasaki R, et al. Isolation and characterization of cDNA encoding rabbit reticulocyte 2,3-bisphosphoglycerate synthase. Gene 1986; 44: 185-91.
25. Omenn GS, Cheung SC,. Phosphoglycerate mutase isozyme marker for tissue differentiation in man. Am J Hum Genet 1974; 26: 393-9.
26. Durany N, Carreras J,. Distribution of phosphoglycerate mutase isozymes in rat, rabbit and human tissues. Comp Biochem Physiol B Biochem Mol Biol 1996; 114: 217-23.
27. Blouquit Y, Calvin MC, Rosa R, et al. Sequence of the human erythrocyte phosphoglycerate mutase by microsequencer and mass spectrometry. J Biol Chem 1988; 263: 16906-10.
28. Rose ZB, Hamasaki N, Dube S,. The sequence of a peptide containing the active site phosphohistidine residue of phosphoglycerate mutase from chicken breast muscle. J Biol Chem 1975; 250: 7939-42.
29. Shanske S, Sakoda S, Hermodson MA, et al. Isolation of a cDNA encoding the muscle-specific subunit of human phosphoglycerate mutase. J Biol Chem 1987; 262: 14612-17.
30. Sakoda S, Shanske S, DiMauro S, et al. Isolation of a cDNA encoding the B isozyme of human phosphoglycerate mutase (PGAM) and characterization of the PGAM gene family. J Biol Chem 1988; 263: 16899-905.
31. Castella-Escola J, Ojcius DM, LeBoulch P, et al. Isolation and characterization of the gene encoding the muscle-specific isozyme of human phosphoglycerate mutase. Gene 1990; 91: 225-32.
32. Warburg O,. On respiratory impairment in cancer cells. Science 1956; 124: 269-70.
33. Vander Heiden MG, Cantley LC, Thompson CB,. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-33.
34. Durany N, Joseph J, Jimenez OM, et al. Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase, creatine kinase and enolase activity and isoenzymes in breast carcinoma. Br J Cancer 2000; 82: 20-7.
35. Durany N, Joseph J, Cruz-Sanchez FF, et al. Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and creatine kinase activity and isoenzymes in human brain tumours. Br J Cancer 1997; 76: 1139-49.
36. Hitosugi T, Zhou L, Elf S, et al. Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell 2012; 22: 585-600.
37. Hamanaka RB, Chandel NS,. Targeting glucose metabolism for cancer therapy. J Exp Med 2012; 209: 211-15.
38. Lunt SY, Vander Heiden MG,. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 2011; 27: 441-64.
39. Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 230-3.
40. Sun Q, Chen X, Ma J, et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA 2011; 108: 4129-34.
41. Bluemlein K, Gruning NM, Feichtinger RG, et al. No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget 2011; 2: 393-400.
42. Cortes-Cros M, Hemmerlin C, Ferretti S, et al. M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. Proc Natl Acad Sci USA 2013; 110: 489-94.
43. Israelsen WJ, Dayton TL, Davidson SM, et al. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 2013; 155: 397-409.
44. Vander Heiden MG, Locasale JW, Swanson KD, et al. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 2010; 329: 1492-9.
45. Jacobowitz DM, Jozwik C, Fukuda T, et al. Immunohistochemical localization of phosphoglycerate mutase in capillary endothelium of the brain and periphery. Microvasc Res 2008; 76: 89-93.
46. Grisolia S, Cleland WW,. Influence of salt, substrate, and cofactor concentrations on the kinetic and mechanistic behavior of phosphoglycerate mutase. Biochemistry 1968; 7: 1115-21.
47. Engel M, Seifert M, Theisinger B, et al. Glyceraldehyde-3-phosphate dehydrogenase and Nm23-H1/nucleoside diphosphate kinase A. Two old enzymes combine for the novel Nm23 protein phosphotransferase function. J Biol Chem 1998; 273: 20058-65.
48. Engel M, Mazurek S, Eigenbrodt E, et al. Phosphoglycerate mutase-derived polypeptide inhibits glycolytic flux and induces cell growth arrest in tumor cell lines. J Biol Chem 2004; 279: 35803-12.
49. Kondoh H, Lleonart ME, Gil J, et al. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005; 65: 177-85.
50. Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126: 107-20.
51. Madan E, Gogna R, Bhatt M, et al. Regulation of glucose metabolism by p53: emerging new roles for the tumor suppressor. Oncotarget 2011; 2: 948-57.
52. Takahashi Y, Takahashi S, Yoshimi T, et al. Hypoxia-induced expression of phosphoglycerate mutase B in fibroblasts. Eur J Biochem 1998; 254: 497-504.
53. Gonzalez-Cinca N, Rivera F, Carreras J, et al. Effects of hypoxia and thyroid hormone on mRNA levels and activity of phosphoglycerate mutase in rabbit tissues. Horm Res 2003; 59: 16-20.
54. Sharma NK, Sethy NK, Bhargava K,. Comparative proteome analysis reveals differential regulation of glycolytic and antioxidant enzymes in cortex and hippocampus exposed to short-term hypobaric hypoxia. J Proteomics 2013; 79C: 277-98.
55. Semenza GL,. HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr 2007; 39: 231-4.
56. Luo W, Semenza GL,. Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget 2011; 2: 551-6.
57. Usuba T, Ishibashi Y, Okawa Y, et al. Purification and identification of monoubiquitin-phosphoglycerate mutase B complex from human colorectal cancer tissues. Int J Cancer 2001; 94: 662-8.
58. Zhao S, Xu W, Jiang W, et al. Regulation of cellular metabolism by protein lysine acetylation. Science 2010; 327: 1000-4.
59. Finkel T, Deng CX, Mostoslavsky R,. Recent progress in the biology and physiology of sirtuins. Nature 2009; 460: 587-91.
60. Haigis MC, Sinclair DA,. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 2010; 5: 253-95.
61. Hallows WC, Yu W, Denu JM,. Regulation of glycolytic enzyme phosphoglycerate mutase-1 by Sirt1 protein-mediated deacetylation. J Biol Chem 2012; 287: 3850-8.
62. Hitosugi T, Zhou L, Fan J, et al. Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation. Nat Commun 2013; 4: 1790.
63. Rigden DJ, Walter RA, Phillips SE, et al. Polyanionic inhibitors of phosphoglycerate mutase: combined structural and biochemical analysis. J Mol Biol 1999; 289: 691-9.